Z-Thr(tBu)-OH

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Z-Thr(tBu)-OH
• 英文别名: 3-[(2-methylpropan-2-yl)oxy]-2-(phenylmethoxycarbonylamino)butanoic acid
• 化学式: C₁₆H₂₃NO₅
• 分子量: 309.36
• InChiKey: QJYMOTAFFJDTAG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  22
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  84.9
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• [EN] 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH<br/>[FR] 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES COMME INHIBITEURS D'IDH MUTANTE
  申请人：NOVARTIS AG

  公开号：WO2014141104A1

  公开（公告）日：2014-09-18

  The invention is directed to a formula (I), or a pharmamceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

  这项发明涉及一种式(I)的配方，或其药用可接受的盐，其中R1、R2a、R2b和R3-R7在此处。该发明还涉及含有式(I)化合物的组合物，以及在抑制具有新型活性的突变IDH蛋白中使用这种化合物的用途。该发明还涉及在治疗与这种突变IDH蛋白相关的疾病或紊乱中使用式(I)化合物，包括但不限于细胞增殖紊乱，如癌症。
• [EN] COMPOUNDS USEFUL FOR THE TREATMENT OF INFECTION WITH MANNHEIMIA HAEMOLYTICA OR HISTOPHILUS SOMNI<br/>[FR] COMPOSÉS UTILES POUR LE TRAITEMENT D'UNE INFECTION PAR MANNHEIMIA HAEMOLYTICA OU HISTOPHILUS SOMNI
  申请人：INTERVET INT BV

  公开号：WO2020002234A1

  公开（公告）日：2020-01-02

  The present invention discloses compounds that are useful in the treatment of respiratory diseases of animals, especially Bovine or Swine Respiratory disease (BRD and SRD)

  本发明公开了一种在治疗动物呼吸道疾病，特别是牛或猪呼吸道疾病（BRD和SRD）方面有用的化合物。
• [EN] PCSK9 ANTAGONIST COMPOUNDS<br/>[FR] COMPOSÉS ANTAGONISTES DU PCSK9
  申请人：MERCK SHARP & DOHME

  公开号：WO2021041770A1

  公开（公告）日：2021-03-04

  Disclosed are compounds of Formula (A), or a pharmaceutically acceptable salt thereof: where A, X, R1, and R2 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula (I) or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.

  本公开了化合物的结构式（A），或其药学上可接受的盐：其中A，X，R1和R2如本文所定义，这些化合物具有拮抗PCSK9的特性。还描述了包含化合物的药物配方（I）或其盐，并且治疗心血管疾病和与PCSK9活性相关的疾病的方法，例如动脉粥样硬化，高胆固醇血症，冠心病，代谢综合征，急性冠状综合征或相关心血管疾病和心脏代谢状况。
• Protease inhibitors
  申请人：Yang Syaulan

  公开号：US20050143319A1

  公开（公告）日：2005-06-30

  This invention relates to treating an infection with a virus using protease inhibitors. Examples of the protease inhibitors include compounds of formula (I). Each variable is defined in the specification.

  这项发明涉及使用蛋白酶抑制剂治疗病毒感染。蛋白酶抑制剂的示例包括公式(I)的化合物。每个变量在说明书中有定义。
• [EN] POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS<br/>[FR] DÉRIVÉS DE POLYMYXINE ET LEUR UTILISATION DANS UNE POLYTHÉRAPIE EN ASSOCIATION AVEC DIFFÉRENTS ANTIBIOTIQUES
  申请人：NEW PHARMA LICENCE HOLDINGS LTD

  公开号：WO2015135976A1

  公开（公告）日：2015-09-17

  Provided are compounds of formula (III), and the use of compounds of formula (III) in methods of treatment, such as methods of treating a microbial infection. The compounds of formula (III) is: where -R15 is an amino-containing group: and -R1, -R2, -R3, -R4, -R8, -RA, Q, -R16, -R17 are as described in further detail in the description.

  提供的是公式(III)的化合物，以及化合物(III)在治疗方法中的应用，例如治疗微生物感染的方法。公式(III)的化合物如下：其中-R15是含氨基的基团；-R1、-R2、-R3、-R4、-R8、-RA、Q、-R16、-R17的具体描述详见说明书。